CA3086407A1 - Pic1 inhibition of myeloperoxidase oxidative activity in an animal model - Google Patents

Pic1 inhibition of myeloperoxidase oxidative activity in an animal model Download PDF

Info

Publication number
CA3086407A1
CA3086407A1 CA3086407A CA3086407A CA3086407A1 CA 3086407 A1 CA3086407 A1 CA 3086407A1 CA 3086407 A CA3086407 A CA 3086407A CA 3086407 A CA3086407 A CA 3086407A CA 3086407 A1 CA3086407 A1 CA 3086407A1
Authority
CA
Canada
Prior art keywords
pic1
dpeg24
mpo
subject
transfusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3086407A
Other languages
English (en)
French (fr)
Inventor
Neel K. Krishna
Kenji Cunnion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Realta Holdings LLC
Original Assignee
Realta Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Realta Holdings LLC filed Critical Realta Holdings LLC
Publication of CA3086407A1 publication Critical patent/CA3086407A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Wood Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
CA3086407A 2018-01-09 2019-01-08 Pic1 inhibition of myeloperoxidase oxidative activity in an animal model Pending CA3086407A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862615183P 2018-01-09 2018-01-09
US62/615,183 2018-01-09
US201862681458P 2018-06-06 2018-06-06
US62/681,458 2018-06-06
US201862746649P 2018-10-17 2018-10-17
US62/746,649 2018-10-17
PCT/US2019/012659 WO2019139886A1 (en) 2018-01-09 2019-01-08 Pic1 inhibition of myeloperoxidase oxidative activity in an animal model

Publications (1)

Publication Number Publication Date
CA3086407A1 true CA3086407A1 (en) 2019-07-18

Family

ID=67140101

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3086407A Pending CA3086407A1 (en) 2018-01-09 2019-01-08 Pic1 inhibition of myeloperoxidase oxidative activity in an animal model

Country Status (12)

Country Link
US (6) US11135272B2 (https=)
EP (2) EP3740074B1 (https=)
JP (2) JP7031011B2 (https=)
KR (2) KR20220104268A (https=)
CN (1) CN112512548A (https=)
AU (2) AU2019207508B2 (https=)
CA (1) CA3086407A1 (https=)
ES (1) ES2996888T3 (https=)
IL (2) IL287308B2 (https=)
MX (3) MX2020007098A (https=)
SG (1) SG11202006063RA (https=)
WO (1) WO2019139886A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10947279B2 (en) 2015-06-26 2021-03-16 Realta Holdings, Llc Synthetic peptide compounds and methods of use
EP3740074B1 (en) 2018-01-09 2024-11-06 ReAlta Holdings, LLC Pic1 inhibition of myeloperoxidase oxidative activity in an animal model
IL301441A (en) * 2020-09-30 2023-05-01 Realta Life Sciences Inc Peptides and methods of use
WO2022094367A1 (en) * 2020-11-02 2022-05-05 Realta Life Sciences, Inc. Peptides and methods of use
WO2022094372A1 (en) * 2020-11-02 2022-05-05 Realta Life Sciences, Inc. Peptides and methods of use
CA3194447A1 (en) * 2020-11-09 2022-05-12 Neel K. Krishna Peptide formulations and methods of use
WO2022179937A1 (en) * 2021-02-26 2022-09-01 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Anti-cleaved histone h3 monoclonal antibody that specifically recognizes neutrophil extracellular traps
JP2024522988A (ja) * 2021-06-01 2024-06-25 レアルタ ライフ サイエンシズ インコーポレイテッド ペプチドおよび使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625049A (en) 1993-05-12 1997-04-29 Us Health Nucleic acids encoding human astrovirus serotype 2
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
AU3066699A (en) 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
AU2729400A (en) 1999-01-19 2000-08-07 James Daly Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease
US6696562B1 (en) 2000-07-10 2004-02-24 The United States Of America As Represented By The Secretary Of Agriculture Avian astrovirus
US20070012617A1 (en) 2003-09-05 2007-01-18 Sadakatsu Suzuki Method for producing micro-porous film of thermoplastic resin
WO2005023296A1 (en) 2003-09-05 2005-03-17 University Of Louisville Research Foundation, Inc. Treatment of rheumatic diseases
WO2005023195A2 (en) 2003-09-05 2005-03-17 University Of Louisville Research Foundation, Inc. Treatment of spinal cord injury
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
US7381524B2 (en) 2003-10-10 2008-06-03 Wisconsin Alumni Research Foundation Method to detect antibodies specific for type-2 turkey astrovirus
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2007145806A2 (en) 2006-06-15 2007-12-21 Eastern Virginia Medical School Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof
US7956161B2 (en) 2007-04-11 2011-06-07 Pestka Biomedical Laboratories, Inc. Interferons of rhesus and cynomolgus origin and uses thereof
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
EP2561367A1 (en) 2010-04-22 2013-02-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations
US10005818B2 (en) 2010-07-21 2018-06-26 Realta Holdings, Llc Derivative peptide compounds and methods of use
ES2688589T3 (es) 2010-07-21 2018-11-05 Eastern Virginia Medical School Compuestos peptídicos para regular el sistema del complemento
CA2867593A1 (en) 2012-03-16 2013-09-19 Belrose Pharma, Inc. Polymeric conjugates of c-1 inhibitors
ES2875498T3 (es) * 2015-06-26 2021-11-10 Realta Holdings Llc Compuestos de péptidos sintéticos y procedimientos de uso
EP3740074B1 (en) 2018-01-09 2024-11-06 ReAlta Holdings, LLC Pic1 inhibition of myeloperoxidase oxidative activity in an animal model

Also Published As

Publication number Publication date
IL287308B2 (en) 2024-03-01
EP3740074A1 (en) 2020-11-25
KR102420552B1 (ko) 2022-07-13
WO2019139886A1 (en) 2019-07-18
MX2020007098A (es) 2020-11-11
IL287308A (en) 2021-12-01
JP7341268B2 (ja) 2023-09-08
IL275867A (en) 2020-08-31
EP4464716A3 (en) 2025-02-19
JP2021509916A (ja) 2021-04-08
EP4464716A2 (en) 2024-11-20
MX2025009081A (es) 2025-09-02
US11712462B2 (en) 2023-08-01
US20210252113A1 (en) 2021-08-19
EP3740074B1 (en) 2024-11-06
US11135272B2 (en) 2021-10-05
US20260021164A1 (en) 2026-01-22
AU2024205230A1 (en) 2024-09-05
AU2019207508B2 (en) 2024-05-02
KR20220104268A (ko) 2022-07-26
JP7031011B2 (ja) 2022-03-07
EP3740074A4 (en) 2021-10-13
US20200230212A1 (en) 2020-07-23
US20250177492A1 (en) 2025-06-05
ES2996888T3 (en) 2025-02-13
IL275867B (en) 2022-01-01
SG11202006063RA (en) 2020-07-29
US11020460B2 (en) 2021-06-01
US20190209660A1 (en) 2019-07-11
JP2022068323A (ja) 2022-05-09
US12257290B2 (en) 2025-03-25
US20230321201A1 (en) 2023-10-12
CN112512548A (zh) 2021-03-16
KR20200138168A (ko) 2020-12-09
AU2019207508A1 (en) 2020-07-09
MX2025009095A (es) 2025-11-03
IL287308B1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
US12257290B2 (en) PIC1 inhibition of myeloperoxidase oxidative activity in an animal model
Hair et al. Inhibition of immune complex complement activation and neutrophil extracellular trap formation by peptide inhibitor of complement C1
Zimmer et al. Danger signaling in atherosclerosis
Stenson et al. The complement system in pediatric acute kidney injury
US20220096592A1 (en) Pic1 variants with improved solubility and methods of using the same
US20220175886A1 (en) Net stabilization as a therapy for sepsis
Krishna et al. The EPICC family of anti-inflammatory peptides: next generation peptides, additional mechanisms of action, and in vivo and ex vivo efficacy
Kulkarni et al. Anticomplement therapy
ES2883952T3 (es) Clusterina para su uso en el tratamiento de microangiopatías trombóticas
Gregory Rivera et al. Incompatible erythrocyte transfusion with lipopolysaccharide induces acute lung injury in a novel rat model
Yin et al. Histone neutralization protects the ischemic brain against stroke-associated pneumonia
Kirschfink et al. The Role of Complement in Kidney Disease
Golubeva Changes in Erythrocytes and Their Degradation Products under the Influence of the SARS-COV-2 Virus
Petr Complement pathophysiology in kidney transplantation
Lazarowski Possible Use of Eculizumab in Critically Ill Patients Infected with Covid-19 Role of Complement C5, Neutrophils, and NETs in the Induction DIC, Sepsis, and MOF
Kotimaa Analysis of systemic complement in experimental renal injury and disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220919

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250103

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250103

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250103

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250328

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250630

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250703